ProPhase Labs Announces Closing of Public Offering of Common Stock
ProPhase Labs announced the closing of its underwritten public offering of 4,795,500 shares of common stock, including 625,500 shares from the underwriter's fully exercised option. Shares were sold at $0.72 per share, generating gross proceeds of approximately $3.45 million. The company plans to use proceeds for working capital, general corporate purposes, capital expenditures, product development, and potential acquisitions. ThinkEquity served as the sole book-running manager for the offering, which was conducted under an effective shelf registration statement.
ProPhase Labs ha annunciato la chiusura della sua offerta pubblica sottoscritta di 4.795.500 azioni di azioni ordinarie, comprese 625.500 azioni derivanti dall'opzione completamente esercitata dell'underwriter. Le azioni sono state vendute a $0,72 per azione, generando proventi lordi di circa $3,45 milioni. L'azienda prevede di utilizzare i proventi per capitale circolante, fini aziendali generali, spese in conto capitale, sviluppo di prodotti e potenziali acquisizioni. ThinkEquity ha svolto il ruolo di unico manager book-running per l'offerta, che è stata condotta sotto una dichiarazione di registrazione a scaffale efficace.
ProPhase Labs anunció el cierre de su oferta pública suscrita de 4,795,500 acciones de acciones ordinarias, incluidas 625,500 acciones de la opción totalmente ejercida del suscriptor. Las acciones se vendieron a $0.72 por acción, generando ingresos brutos de aproximadamente $3.45 millones. La empresa planea utilizar los ingresos para capital de trabajo, propósitos corporativos generales, gastos de capital, desarrollo de productos y posibles adquisiciones. ThinkEquity actuó como el único administrador de la oferta, que se llevó a cabo bajo una declaración de registro de estantería efectiva.
ProPhase Labs는 4,795,500주의 보통주에 대한 인수공모의 마감을 발표했습니다. 여기에는 인수자의 완전히 행사된 옵션으로부터 625,500주가 포함됩니다. 주식은 주당 $0.72에 판매되어 약 $3.45 백만의 총 수익을 창출했습니다. 회사는 수익금을 운영 자본, 일반 회사 용도, 자본 지출, 제품 개발 및 잠재적 인수에 사용할 계획입니다. ThinkEquity는 이 공개모집의 유일한 북런닝 매니저로 활동했으며, 이는 유효한 선등록신청서에 따라 실시되었습니다.
ProPhase Labs a annoncé la clôture de son offre publique souscrite d'4 795 500 actions de capital social, y compris 625 500 actions provenant de l'option entièrement exercée du souscripteur. Les actions ont été vendues à 0,72 $ par action, générant des recettes brutes d'environ 3,45 millions $. La société prévoit d'utiliser les recettes pour le fonds de roulement, des fins générales de l'entreprise, des dépenses d'investissement, le développement de produits et de potentielles acquisitions. ThinkEquity a agi en tant que gestionnaire principal de cette offre, qui a été réalisée sous une déclaration d'enregistrement de type étagère valide.
ProPhase Labs hat den Abschluss seines unterzeichneten öffentlichen Angebots von 4.795.500 Aktien des Stammkapitals angekündigt, einschließlich 625.500 Aktien aus der vollständig ausgeübten Option des Underwriters. Die Aktien wurden zu einem Preis von $0,72 pro Aktie verkauft, was einen Bruttoerlös von etwa $3,45 Millionen generierte. Das Unternehmen plant, die Erlöse für Betriebskapital, allgemeine Unternehmenszwecke, Investitionsausgaben, Produktentwicklung und potenzielle Akquisitionen zu verwenden. ThinkEquity fungierte als alleiniger Buchführer für das Angebot, das unter einer effektiven Shelf-Registrierungsanmeldung durchgeführt wurde.
- Successful completion of public offering raising $3.45 million in gross proceeds
- Full exercise of underwriter's option indicating strong demand
- Flexible use of proceeds allowing for strategic investments and growth initiatives
- Significant shareholder dilution through issuance of 4,795,500 new shares
- Low offering price of $0.72 per share indicates weak market conditions
- Additional capital raise suggests potential cash flow concerns
Insights
This public offering raises significant concerns about ProPhase Labs' financial position. The
GARDEN CITY, NY, Nov. 12, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs, Inc. (NASDAQ: PRPH) (“ProPhase” or the “Company”), a next-generation biotech, genomics and diagnostics company, today announced the closing of its previously announced underwritten public offering of 4,795,500 shares of its common stock, including 625,500 shares sold upon full exercise of the underwriter's option to purchase additional shares. Each share of common stock was sold at a public offering price of
The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, which may include capital expenditures, product development and commercialization expenditures, and acquisitions of companies, businesses, technologies and products within and outside the diagnostic services, genomics and consumer products industry.
ThinkEquity acted as sole book-running manager for the offering.
The offering was made pursuant to an effective shelf registration statement on Form S-3 (File No. 333-260848), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 5, 2021 and declared effective on November 12, 2021. The final prospectus supplement relating to the offering was filed with the SEC on November 8, 2024 and is available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
About ProPhase Labs
ProPhase Labs, Inc. (Nasdaq: PRPH) is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight. We believe we are revolutionizing healthcare with industry-leading Whole Genome Sequencing solutions, while developing potential game changer diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Our world-class CLIA labs and cutting-edge diagnostic technology provide wellness solutions for healthcare providers and consumers. We develop, manufacture, and commercialize health and wellness solutions to enable people to live their best lives. We are committed to executional excellence, smart diversification, and a synergistic, omni-channel approach. ProPhase Labs' subsidiaries and their strategic synergies highlight our potential for long-term value.
For more information, visit www.ProPhaseLabs.com
Forward-Looking Statements
This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms and similar expressions intended to identify forward-looking statements. These statements include statements related to the intended use of proceeds. ProPhase cautions readers that forward-looking statements are based on management’s expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially, including, but not limited to, risks related to prevailing market conditions, the impact of general economic, industry or political conditions in the United States, and ProPhase’s ability to satisfy customary closing conditions associated with the offering. Management believes that these forward-looking are reasonable as and when made. Forward-looking statements reflect its analysis only on their stated date, and ProPhase undertakes no obligation to update or revise these statements except as may be required by law.
Media Relations and Institutional Investor Contact:
ProPhase Labs, Inc.
267-880-1111
investorrelations@prophaselabs.com
Retail Investor Relations Contact:
Renmark Financial Communications
John Boidman
514-939-3989
Jboidman@renmarkfinancial.com
FAQ
How much did ProPhase Labs (PRPH) raise in its November 2024 public offering?
What was the price per share for PRPH's November 2024 public offering?
How will ProPhase Labs use the proceeds from its 2024 public offering?